Novel Developments in the Multimodality Treatment of Esophageal Cancer (Ongoing)

Posted On 2020-03-04 08:16:40

This focused issue on “Novel Developments in the Multimodality Treatment of Esophageal Cancer” is edited by Drs. Sjoerd Lagarde and Bas Wijnhoven, from Erasmus Medical Center, Rotterdam, The Netherlands; and Dr. Florian Lordick, from Universitätsklinik Leipzig, Leipzig, Germany.

This focused issue is designed to discuss updates in novel developments in the multimodality treatment of esophageal cancer. Complex and controversial issues that are on the minds of many will be addressed by experts such as yourself. This focused issue reviews recent literature, provides expert insight into current practice, and also identifies future directions.

Sjoerd Lagarde, MD, PhD
Erasmus Medical Center, Rotterdam, The Netherlands

Dr. Sjoerd Lagarde is a Dutch upper-GI surgeon who was trained as an upper GI surgeon in the Academic Medical Center (AMC) in Amsterdam, the Netherlands and at the Oesophagogastric unit in The Royal Victoria Infirmary in Newcastle-Upon-Tyne, UK. Currently he is an Upper-GI surgeon in the Erasmus Medical Center in Rotterdam, the Netherlands. The Erasmus Medical Center is one of the largest upper GI centers in the Netherlands, and has a strong record in important clinical trials in esophageal cancer (e.g. the CROSS study and the current SANO study).

Bas Wijnhoven, MD, PhD
Erasmus Medical Center, Rotterdam, The Netherlands

Since 2008 Dr. Wijnhoven is appointed as staff surgeon at the Erasmus MC Rotterdam and is program leader on oesophageal and gastric diseases. His clinical interests are benign and malignant diseases of the upper gastrointestinal tract. Research is focused on studies on clinical outcome after surgery for gastric and oesophageal cancer and the molecular biology of Barrett’s oesophagus and adenocarcinoma. In close collaboration with other departments within the Erasmus MC, preclinical and clinical studies on neoadjuvant treatment for oesophageal and gastric cardia cancer are another area of great interest. Dr. Wijnhoven is interested in medical publishing and served as full-editor of BJS. He has authored and co-authored over 230 articles in national and international peer-reviewed journals.

Florian Lordick, MD, PhD
Universitätsklinik Leipzig, Leipzig, Germany

Dr. Lordick is a Full Professor of Oncology at the Leipzig University, Germany. He is director of the University Cancer Center Leipzig in since 2012. In 2018, he was additionally appointed as Director of the department of oncology at the University Hospital Leipzig, Germany.

Dr. Lordick is a member of the board of directors of the German Cancer Society (DKG). He is chairman of the EORTC GI Tract Cancer Working Group (2018-2020) and since 2020 he is director of education of the Eiropean Society for Medical Oncology. He is the current President of the International Gastric Cancer Association (IGCA; 2019-2021).

Dr. Lordick’s scientific focus is the clinical and translational research in gastrointestinal cancer, particularly in gastric and esophageal cancer. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commision. Dr. Lordick has authored and co-authored more than 300 peer-reviewed articles. He is editor-in-chief of Forum (Soringer), the official journal of the German Cancer Society, editor of Gastric Cancer (Springer), the official journal of IGCA and editorial board member of Annals of Oncology, the official journal of ESMO, and Gastric Cancer.

Focused issue outline:

The complete outline of this focused issue is listed below:

  1. Introduction to the focused issue
  2. Indications for endoscopic treatment for adeno- and squamous cell cancer of the esophagus
  3. Esd/emr for t1b cancer of the esophagus
  4. Salvage esd after chemoradiation therapy
  5. Adjuvant therapy after esophagectomy
  6. Ibs and abs in the treatment of esophageal cancer
  7. Indications for definitive chemoradiotherapy for esophageal cancer
  8. Active surveillance after chemoradiation therapy
  9. Open vs. Hybrid vs. Minimally invasive esophagectomy  
  10. Learning curve issues in esophagectomy
  11. Salvage surgery after definitive chemoradiotherapy for esophageal cancer
  12. How to treat dysphagia: stent or rt? 
  13. Surgery for synchronic metastasized esophageal cancer
  14. Surgery for metachronic metastasized esophageal cancer 
The series “Novel Developments in the Multimodality Treatment of Esophageal Cancer” was commissioned by the editorial office, Annals of Esophagus without any sponsorship or funding. Sjoerd Lagarde, Bas Wijnhoven and Florian Lordick are serving as the unpaid Guest Editors for the series.